The groundbreaking rise of copyright’s flagship product presented a considerable chance for shareholders , but its patent has ended, creating a challenging landscape. Off-brand versions have appeared in the arena, eroding profits and putting a squeeze on profit yields. While established drug companies hold a foothold in this field , the outlook r